Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1253 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 44.45 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 50.82 | Oscillator | Neutral |
| Williams %R (14) | -45.90 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.19 (Hist 0.04) | Oscillator | Buy |
| Average Directional Index (14) | 38.98 (+DI 15.2 / -DI 23.3) | Trend | Strong Sell |
Current price $2.97
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Jul 31, 24 | HC Wainwright & Co. |
| EMA 20 | 3.07 | MA | Strong Sell |
| SMA 20 | 2.98 | MA | Sell |
| EMA 50 | 3.64 | MA | Strong Sell |
| SMA 50 | 3.58 | MA | Strong Sell |
| SMA 200 | 5.93 | MA | Strong Sell |
| upgrade |
| Neutral |
| Buy |
| Jun 22, 22 | HC Wainwright & Co. | downgrade | Buy | Neutral |
| May 30, 22 | HC Wainwright & Co. | maintain | Buy | Buy |
| Feb 10, 22 | HC Wainwright & Co. | maintain | Buy | Buy |
FY2024 · 10-K disclosure
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 2, 26 | Teyssedou Lenaic Nathanael | officer: PRINCIPAL ACCOUNTING OFFICER | A-Award | 100,485 @ $0.032 | $3.22K |
| Sep 2, 26 | Teyssedou Lenaic Nathanael | officer: PRINCIPAL ACCOUNTING OFFICER | D-Return | 10,000 @ $0.16 | $1.60K |
| Sep 2, 26 | Teyssedou Lenaic Nathanael | officer: PRINCIPAL ACCOUNTING OFFICER | D-Return | 30,000 @ $0.16 | $4.80K |
| Sep 2, 26 | Teyssedou Lenaic Nathanael | officer: PRINCIPAL ACCOUNTING OFFICER | D-Return | 37,770 @ $0.16 | $6.04K |
| Sep 2, 26 | Teyssedou Lenaic Nathanael | officer: PRINCIPAL ACCOUNTING OFFICER | D-Return | 59,530 @ $0.16 | $9.52K |
| Sep 2, 26 | Teyssedou Lenaic Nathanael | officer: PRINCIPAL ACCOUNTING OFFICER | D-Return | 65,620 @ $0.16 | $10.50K |
| Sep 2, 26 | Teyssedou Lenaic Nathanael | officer: PRINCIPAL ACCOUNTING OFFICER | D-Return | 90,529 @ $0.16 | $14.48K |
| Sep 2, 26 | Teyssedou Lenaic Nathanael | officer: PRINCIPAL ACCOUNTING OFFICER | D-Return | 100,485 @ $0.062 | $6.23K |
TTM vs. 5-year historical average (annual ratios)
| Metric | ADXN | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.5x | -0.6x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -0.6x | EPS est. -4.74 | Elevated |
| Price / Book | 2.1x | 1.5x | Elevated |
| Price / Sales | 45.6x | 44.0x | In line |
| EV / EBITDA | -0.6x | -0.3x | Elevated |
| Return on equity | -172.8% | — | Weak |
| Gross margin | 41.2% | 100.0% | Below hist. |
| Debt / Equity | 0.04 | 0.08 | Conservative |
| Piotroski / Altman Z | 2/9 | Z -150.61 | Distress |
Discounted cash flow model
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 6-K | Oct 8, 2026 | 2026-10-08 06:05:05 | View |
| 6-K | Oct 2, 2026 | 2026-10-02 06:05:05 | View |
| 6-K | Sep 28, 2026 | 2026-09-28 07:06:37 | View |
| 6-K | Sep 25, 2026 | 2026-09-25 06:05:04 | View |
| 4 | Sep 4, 2026 | 2026-09-04 16:11:06 | View |
| 4 | Sep 4, 2026 | 2026-09-04 16:09:46 | View |
| 4 | Sep 4, 2026 | 2026-09-04 16:06:52 | View |
| 4 | Sep 4, 2026 | 2026-09-04 16:05:24 | View |
| 4 | Sep 4, 2026 | 2026-09-04 16:03:30 | View |
| 4 | Sep 4, 2026 | 2026-09-04 16:02:09 | View |
Proxy statement (DEF 14A) disclosures
Stock news · updated daily
Clene (NASDAQ: CLNN - Get Free Report) and Addex Therapeutics (NASDAQ: ADXN - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings and valuation. Profitability This table compares Clene and Addex Therapeutics'
What happened Addex Therapeutics Ltd. (NASDAQ: ADXN) said Neurosterix completed Phase 1 studies of NTX-253 and plans to move the drug into Phase 2. NTX-253 is a positive allosteric modulator of the muscarinic M4 receptor, and the program is being developed for schizophrenia. Addex said Neurosterix is its spin-out company and that Addex holds a
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 8, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, in which Addex holds a 20% equity interest, has completed its Phase 1 clinical studies evaluating NTX-253 and plans to advance NTX-253 into Phase 2 clinical development.
Jean-Philippe Rocher Appointed Head of Pharmaceutical Development Mikhail Kalinichev, Head of Translational Science, Steps Down Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 2, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced the appointment of Jean-Philippe Rocher as Head of Pharmaceutical Development and member of the Executive Management.
Addex Therapeutics (NASDAQ: ADXN) reported a CHF 1.1 million operating loss for the first half of 2026, compared with CHF 1.3 million a year earlier, as reduced outsourced research and development spending on its GABAB positive allosteric modulator, or PAM, program lowered expenses. Chief Executive Officer Tim Dyer said the company also raised $2.8 million through
Addex Therapeutics Ltd (ADXN) Q2 2026 Earnings Call Transcript
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 28, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its 2026 Half-Year and Second Quarter financial results and provided a corporate update.
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 25, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company developing novel small molecule allosteric modulators for neurological disorders, today announced that it has regained full global rights to all GABAB positive allosteric modulator (PAM) assets discovered under its research collaboration with Indivior UK Limited (“Indivior”).
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Sep 28, 2026 | — | -1.49 | — | $12.32K |
| Jun 25, 2026 | — | -1.53 | — | $9.88K |
| Apr 30, 2026 | -1.42 | -1.94 | Miss -36.0% | $313.0K |
| Dec 4, 2025 | — | -1.50 | — | $37.36K |
| Nov 10, 2025 | -1.42 | -2.91 | Miss -104.4% | $45.25K |
| Jun 20, 2025 | -4.26 | -1.33 | Beat 68.8% | — |